Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma

Trial Profile

A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms JAVELIN Merkel 200
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 30 May 2020 Results (n=29) assessing patient experience with avelumab in treatment-naive patients with merkel cell carcinoma, published in The Patient - Patient-Centered Outcomes Research.
    • 20 May 2020 Results presented at the 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 22 Oct 2019 According to an EMD Serono media release, three-year results from Part A (n=88) of this study will be presented at the First International Symposium on Merkel Cell Carcinoma.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top